Research across Diabetic neuropathy
Related studies from across the Diabetic neuropathy family.
21 trials tracked for Diabetic foot: 6 in phase 3 or 4 and 2 with published results. The most-cited published study has 118 citations.
Showing the 21 most-cited and recently-updated of 21 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Treatment of diabetic foot ulcers with topical agents shows evidence of efficacy in reducing wound size and promoting healing. Santyl demonstrated a mean percent change in ulcer area from baseline to the end of treatment of 57.6% and 41.3% 2. Similarly, ON101 Cream showed high success rates for significant reduction, with 101% and 98% of participants achieving at least a 50% reduction in ulcer surface area 3.
Pharmacological management of infections associated with diabetic foot involves several agents. Moxifloxacin demonstrated high rates of clinical improvement during treatment (98.3% to 99.0% in the Per Protocol population) and significant cure rates at the test of cure visit (80.9% to 89.6% in the Intent to Treat population) 6. Tigecycline was also evaluated for clinical response, with various counts of patients achieving 'cure' versus 'failure' or 'indeterminate' outcomes recorded over a period of 25-27 weeks post-last dose 7.
Topical pexiganan cream 0.8% has been evaluated in multiple trials as an intervention for the condition [4, 5].
AI synthesis of 9 cited trials, updated Jun 25, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
Related studies from across the Diabetic neuropathy family.